Receive our newsletter – data, insights and analysis delivered to you

Osteoarthritis accounts for 26.2% share of global Musculoskeletal Disorders clinical trial activity in 2020

Osteoarthritis accounted for a 26.2% share of the global clinical trials within the Musculoskeletal Disorders therapy area in 2020, registering a decrease of 0.5% when compared with the last ten-year average of 26.7% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Osteoarthritis

Industry sponsored trials held a 37.6% share of all the clinical trials for Osteoarthritis indication in 2020, registering a decrease of 0.5% when compared with the ten-year average of 38.1%. Non-industry sponsored trials accounted for a 62.4% share in 2020, registering an increase of 0.5% over the ten-year average of 61.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Osteoarthritis trials

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Asia-Pacific was the top region for industry sponsored Osteoarthritis trials, accounting for a 63.9% share in 2020, when compared with the five-year average of 45.6% and ten-year average of 42.1%.

North America was at the second position with a 26.5% share in 2020, over the five-year average of 32.4% and ten-year average of 31.1%, followed by Europe with an 18.1% share in 2020, as against five-year and ten-year averages of 28.6% and 31.5% respectively.

Middle East and Africa stood fourth with a 1.2% share in 2020, compared with the five-year average of 2.5% and ten-year average of 2.1%, followed by South and Central America with a 0.0% share in 2020, over five-year and ten-year averages of 2.9% and 2.9% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

The US was the top country for industry sponsored Osteoarthritis trials, accounting for a 24.1% share in 2020, as against the five-year average of 28.7% and ten-year average of 27.9%.

China held a 19.3% share in 2020, over the five-year average of 15.3% and ten-year average of 9.8%, followed by India with a 15.7% share in 2020, compared with the five-year and ten-year averages of 10.1% and 11.0% respectively.

Australia held an 8.4% share in 2020, as against the five-year average of 7.1% and ten-year average of 5.9%.

Russia held a 7.2% share in 2020, over the five-year and ten-year averages of 4.6% and 5.9% respectively.

Top regions of non-industry sponsored Osteoarthritis trials

Asia-Pacific was the top region for non-industry sponsored Osteoarthritis trials, accounting for a 55.0% share in 2020 when compared with the five-year average of 51.8% and ten-year average of 44.4%.

North America was at the second position with a 26.0% share in 2020, over the five-year and ten-year averages of 16.1% and 16.8% respectively, followed by Europe with a 13.0% share in 2020, as against the five-year average of 13.7% and ten-year average of 19.9%.

Middle East and Africa stood at the fourth position with a 5.3% share in 2020, compared with the five-year average of 15.9% and ten-year average of 15.6%, followed by South and Central America with a 0.8% share in 2020, over the five-year and ten-year averages of 2.6% and 3.3% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Osteoarthritis trials, accounting for a 28.2% share in 2020, as against the five-year average of 19.3% and ten-year average of 12.8%.

The US held a 21.4% share in 2020, over the five-year average of 12.9% and ten-year average of 14.5%, followed by India with an 11.5% share, compared with the five-year and ten-year averages of 10.2% and 9.7% respectively.

Canada held a 3.8% share in 2020, as against the five-year average of 2.5% and ten-year average of 1.7%.

South Korea held a 3.8% share in 2020, over the five-year average of 4.2% and ten-year average of 3.8%.

Phase II trials lead industry sponsored clinical trials for Osteoarthritis in 2020

Phase II trials held a 43.0% share of industry sponsored clinical trials for Osteoarthritis in 2020, over the five-year average of 41.5% and ten-year average of 39.9%.

Phase III trials held a 24.4% share in 2020, as against the five-year average of 24.5% and ten-year average of 29.0%. Phase I trials held a 20.9% share in 2020, compared with the five-year and ten-year averages of 22.2% and 18.2% respectively.

Phase IV trials held an 11.6% share in 2020, over the five-year average of 11.8% and ten-year average of 13.0%.

Phase II trials lead non-industry sponsored clinical trials for Osteoarthritis in 2020

Phase II trials held a 46.2% share of non-industry sponsored clinical trials for Osteoarthritis in 2020, over the five-year average of 55.5% and ten-year average of 53.9%.

Phase IV trials held a 23.1% share in 2020, as against the five-year average of 20.3% and ten-year average of 22.9%. Phase I trials held a 20.3% share, compared with the five-year and ten-year averages of 7.7% and 6.6% respectively.

Phase III trials held a 10.5% share in 2020, over the five-year average of 16.5% and ten-year average of 16.6%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU